Codexis Inc
CDXS
查看详细走势图
1.695USD
+0.035+2.11%
交易中 （美东）报价延迟15分钟
153.03M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.11%
5天
+1.50%
1月
+10.06%
6月
-25.98%
今年开始到现在
-64.47%
1年
-67.90%
查看详细走势图
TradingKey Codexis Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Codexis Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名105/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.58。中期看，股价处于下降通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Codexis Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
6.583
目标均价
+242.88%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Codexis Inc亮点
亮点风险
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
业绩增长期
公司处于发展阶段，最新年度总收入59.34M美元
利润高增长
公司净利润处于行业前列，最新年度总收入59.34M美元
估值高估
公司最新PE估值-2.26，处于3年历史高位
机构减仓
最新机构持股63.79M股，环比减少4.77%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值8.40K
活跃度增加
近期活跃度增加，过去20天平均换手率0.67
Codexis Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Codexis Inc简介
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
公司代码CDXS
公司Codexis Inc
CEOMoore (Alison)
网址https://www.codexis.com/
常见问题
Codexis Inc(CDXS)的当前股价是多少？
Codexis Inc(CDXS)的当前股价是 1.695。
Codexis Inc的股票代码是什么？
Codexis Inc的股票代码是CDXS。
Codexis Inc股票的52周最高点是多少？
Codexis Inc股票的52周最高点是5.505。
Codexis Inc股票的52周最低点是多少？
Codexis Inc股票的52周最低点是1.520。
Codexis Inc的市值是多少？
Codexis Inc的市值是153.03M。
Codexis Inc的净利润是多少？
Codexis Inc的净利润为-65.28M。
现在Codexis Inc(CDXS)的股票是买入、持有还是卖出？
根据分析师评级，Codexis Inc(CDXS)的总体评级为买入，目标价格为6.583。
Codexis Inc(CDXS)股票的每股收益（EPS TTM）是多少
Codexis Inc(CDXS)股票的每股收益（EPS TTM）是-0.736。
相关品种
